CHR-1103
Posted: Thu Jan 25, 2007 4:03 pm
Chromos reports preclinical data in support of CHR-1103 as an acute therapy for relapse associated with multiple sclerosis
Brain Pathology paper has implications for treatment of MS.
Chromos Molecular Systems Inc. announced today the publication of a paper entitled "Modulation of Experimental Autoimmune Encephalomyelitis by VLA-2 Blockade" in the peer-reviewed scientific journal, Brain Pathology. This paper, authored in collaboration with Dr. Robert Fujinami of the University of Utah School of Medicine, demonstrates that a monoclonal antibody directed against VLA-2, the target for Chromos' lead product candidate CHR-1103, can suppress the clinical and pathological signs of disease in a relevant animal model of multiple sclerosis (MS). In addition, the publication validates VLA-2 as a potential target for early therapeutic intervention in the treatment of MS. This data represents a significant milestone in the development of CHR-1103 as an acute treatment for relapses associated with MS.
"We are very pleased with the release of this data as it represents the culmination of a tremendous body of work in support of the development of CHR-1103 as an acute treatment for MS relapse," said Alistair Duncan, President and CEO. "Currently, there are no FDA approved therapies for MS patients suffering from a relapse. CHR-1103 represents a promising new approach for the treatment of MS relapse and disease compared to the existing portfolio of chronically administered treatments."
CHR-1103 is a humanised monoclonal antibody being developed as a broad-based anti-inflammatory agent, with an initial focus on the treatment of acute relapses associated with MS. Unlike therapeutics designed to delay or antagonise the initial stages of inflammation, CHR-1103 is designed to reduce and prevent the accumulation of inflammatory cells within inflamed tissues. This distinction, i.e., the targeting of ongoing inflammation with CHR-1103, may provide a significant advantage for the acute treatment of inflammatory conditions and/or diseases.
Chromos completed its first meeting with officials from the U.S. Food and Drug Administration (FDA) for CHR-1103 in Q3 2006. The two parties discussed Chromos' clinical approach, proposed preclinical safety evaluation program and manufacture of CHR-1103. Chromos is now moving forward with preclinical safety evaluation studies in preparation for an Investigational New Drug (IND) application in Q4 2007.
Brain Pathology paper has implications for treatment of MS.
Chromos Molecular Systems Inc. announced today the publication of a paper entitled "Modulation of Experimental Autoimmune Encephalomyelitis by VLA-2 Blockade" in the peer-reviewed scientific journal, Brain Pathology. This paper, authored in collaboration with Dr. Robert Fujinami of the University of Utah School of Medicine, demonstrates that a monoclonal antibody directed against VLA-2, the target for Chromos' lead product candidate CHR-1103, can suppress the clinical and pathological signs of disease in a relevant animal model of multiple sclerosis (MS). In addition, the publication validates VLA-2 as a potential target for early therapeutic intervention in the treatment of MS. This data represents a significant milestone in the development of CHR-1103 as an acute treatment for relapses associated with MS.
"We are very pleased with the release of this data as it represents the culmination of a tremendous body of work in support of the development of CHR-1103 as an acute treatment for MS relapse," said Alistair Duncan, President and CEO. "Currently, there are no FDA approved therapies for MS patients suffering from a relapse. CHR-1103 represents a promising new approach for the treatment of MS relapse and disease compared to the existing portfolio of chronically administered treatments."
CHR-1103 is a humanised monoclonal antibody being developed as a broad-based anti-inflammatory agent, with an initial focus on the treatment of acute relapses associated with MS. Unlike therapeutics designed to delay or antagonise the initial stages of inflammation, CHR-1103 is designed to reduce and prevent the accumulation of inflammatory cells within inflamed tissues. This distinction, i.e., the targeting of ongoing inflammation with CHR-1103, may provide a significant advantage for the acute treatment of inflammatory conditions and/or diseases.
Chromos completed its first meeting with officials from the U.S. Food and Drug Administration (FDA) for CHR-1103 in Q3 2006. The two parties discussed Chromos' clinical approach, proposed preclinical safety evaluation program and manufacture of CHR-1103. Chromos is now moving forward with preclinical safety evaluation studies in preparation for an Investigational New Drug (IND) application in Q4 2007.
That day happened to be a good day for MS research news. Personally I like to think of myself as an investigative crusader for MS!! Not really since I barely understand half the stuff I post 
Most of the time I have to wait until others can explain it to me. Research progress is what keeps me going.